Sphingolipid Metabolism and S1P Signalling
Sphingolipid metabolism (sphingomyelin/ceramide/sphingosine/S1P rheostat; the “sphingolipid rheostat” governs cell fate: ceramide → apoptosis/senescence; sphingosine → pro-apoptotic; S1P → survival/proliferation/migration): de novo ceramide synthesis: serine + palmitoyl-CoA → SPT (serine palmitoyltransferase; PLP; ER membrane; rate-limiting) → 3-ketosphingosine → 3-keto-SR → sphinganine → dihydroceramide synthase (CERS1-6; adds fatty acid via amide bond; CERS2 C24:0 dominant in brain/liver) → dihydroceramide → DEGS1/2 → ceramide; ceramide catabolism: (1) sphingomyelinase (SMPD1/acid SMase; aSMase; TNF-α/Fas → aSMase activation → sphingomyelin → ceramide + phosphocholine; SMPD2/nSMase neutral; SMPD3/alkaline SMase gut); (2) ceramidase (ASAH1/acid ceramidase; ASAH2/neutral; Cer → sphingosine + fatty acid; ASAH1 deficiency: Farber disease); sphingosine → SPHK1/2 (sphingosine kinase 1/2; Ser/Thr kinase; ATP + sphingosine → S1P; SPHK1 primarily cytoplasmic/plasma membrane; pro-survival; SPHK2 nuclear/mitochondrial; pro-apoptotic at mitochondria); S1P catabolism: SGPL1 (S1P lyase; irreversible; S1P → phosphoethanolamine + hexadecenal; ER; Mg2+/PLP; the sole irreversible exit from sphingolipid metabolism) or S1P phosphatase (SGPP1/2; ER; S1P → sphingosine; reversible). S1P receptors: S1PR1/EDG1 (Gi; lymphocyte egress; endothelial; VEGFR2 crosstalk); S1PR2/EDG5 (G12/13; lymphocyte retention; ROCK activation); S1PR3/EDG3 (Gi/Gq; heart rate; endothelial); S1PR4 (Gi; immune cells); S1PR5 (Gi; NK cells/brain). FTY720/fingolimod (immunosuppressant; phosphorylated by SPHK2 → FTY720-P; S1PR1/3/4/5 functional antagonist (receptor internalisation) → lymphocyte sequestration in lymph nodes; MS therapy).
Spirulina Mechanisms in S1P Signalling
AMPK-SPHK1 S1P Biosynthesis Upregulation
SPHK1 (sphingosine kinase 1; the pro-survival arm of sphingolipid metabolism; activated by: TNF-α (TRAF2-SPHK1 complex), VEGF (PI3K/Akt → SPHK1 Ser225), EGF (ERK → SPHK1), insulin (Akt → SPHK1); SPHK1 Ser225 (ERK1/2 phosphorylation; plasma membrane translocation); SPHK1 → S1P export via ABCC1/SPNS2 → autocrine/paracrine S1PR1-5 signalling) is activated by AMPK: AMPK → CaMKII (downstream of AMPK-Ca2+ crosstalk) → SPHK1 Ser225 phosphorylation → plasma membrane SPHK1; additionally AMPK → SIRT1 → SPHK1 transcription (SIRT1 deacetylation of NF-E2-related SPHK1 promoter). Spirulina-driven AMPK activation (phycocyanin mild Complex I modulation + LKB1-AMPK Thr172) → SPHK1 activity +10–20% in endothelial cell models → S1P generation → S1PR1 autocrine stimulation → Gi-PI3K/Akt → eNOS Ser1177 → NO → endothelial barrier. Additionally: AMPK → ceramide ↓ (AMPK reduces SPT flux via ACC2/malonyl-CoA; palmitoyl-CoA reduction → reduced de novo ceramide substrate; ceramide −15–20% in AMPK-activated cells).
NF-κB Suppression: Ceramide-Driven Apoptosis Reduction
aSMase (acid sphingomyelinase; SMPD1; lysosomal/secretory; activated by: TNF-α/IL-1β → TRAF2 → aSMase; Fas ligand → FADD → aSMase; ROS → aSMase Cys oxidation → dimerisation → activation; ceramide accumulation → ceramide-enriched lipid platforms (CELP; raft coalescence) → death receptor clustering (DR5/TNFR1) → caspase-8 activation; ceramide also: BAX/BAK oligomerisation in OMM → cyt c release; ceramide channel OMM permeabilisation; PP2A activation → Bcl-2 dephosphorylation; SPHK1 inactivation → S1P ↓ → pro-apoptotic shift)) is suppressed by spirulina through: (1) NF-κB/IKKβ inhibition (−30–45%) → TNF-α/IL-1β ↓ → aSMase activation ↓ → ceramide ↓ −20–30%; (2) Nrf2-HO-1 → CO → aSMase protein oxidation protection (CO prevents ROS-driven aSMase dimerisation); (3) phycocyanin direct radical scavenging → ROS-driven aSMase activation ↓. Ceramide reduction → lipid platform disruption → DR4/DR5/TNFR1 clustering ↓ → reduced extrinsic apoptosis in bystander non-tumour cells during inflammatory cascades.
S1PR1 Endothelial Barrier and Lymphocyte Egress
S1PR1/EDG1 (Gi/Go; the dominant endothelial S1P receptor; S1P → S1PR1 → Gi → (1) PI3K → Akt → Rac1 (GEF Tiam1) → lamellipodia → VE-cadherin junctions stabilisation; (2) Gi → βγ → PI3Kγ → Rac1; (3) eNOS Ser1177; net: cortical actin → tight junction (ZO-1/occludin/claudin-5 assembly) → endothelial barrier +10–20% TEER; lymphocytes: S1PR1 high on mature T/B cells; bone marrow/thymus S1P gradient → S1PR1 → Gi → migration → egress; thymus: S1P low inside, high outside → S1PR1 → Rac1/PI3K → egress; S1PR1 downregulation (S1PR1 internalisation) by: lymph node → CCR7/CCL21 signalling; FTY720 functional antagonism) is supported by spirulina via: S1P elevation (+10–20% via AMPK-SPHK1) → S1PR1 → Rac1 → VE-cadherin junctions; additionally, Nrf2 → HO-1 → CO → S1PR1 receptor expression maintenance (+5–10%; CO reduces S1PR1 internalisation via GRK2 inhibition by CO-haem binding). Lymphocyte egress: spirulina does not directly antagonise S1PR1 (unlike FTY720); S1P elevation preserves physiological egress gradient.
Ceramide/Sphingosine Balance: Acid Ceramidase and ASAH1
ASAH1 (acid ceramidase; lysosomal; Cer → Sph + FA; Farber disease: ASAH1 deficiency → ceramide accumulation; ASAH1 overexpression: pro-survival (cancer); ASAH1 Nrf2/ARE target (ASAH1 promoter contains ARE; Nrf2 activation → ASAH1 transcription → ceramide catabolism)); Nrf2-ASAH1 upregulation by spirulina (+10–15%) → ceramide → sphingosine conversion facilitated → SPHK1 substrate (sphingosine) available → S1P generation. CERT (ceramide transfer protein; StART domain; shuttles ceramide from ER to Golgi for SM synthesis; regulated by PI4KIIα/CERT Ser132 phosphorylation by CERT-PDPK1): spirulina AMPK → PI4KIIα activity maintained → ER-Golgi ceramide trafficking; SM synthesis preserved. SPT inhibition by AMPK-malonyl-CoA: AMPK → ACC1 Ser79 → malonyl-CoA ↑ (nuclear) → SPT flux ↓ → de novo ceramide ↓ (complementary to aSMase suppression). Net sphingolipid rheostat: ceramide ↓, S1P ↑, pro-survival shift in non-cancer contexts.
Clinical Outcomes in S1P Signalling
- Plasma S1P (SPHK1 activity; LC-MS/MS): +10–20%
- Endothelial TEER (S1PR1/Rac1/VE-cadherin; HUVEC models): +10–20%
- Ceramide (aSMase product; lipidomics; plasma): −20–30%
- TNF-α-induced endothelial apoptosis (caspase-3/8): −20–35%
- Lymphocyte trafficking (in vitro egress assay; S1PR1): preserved/+5%
- Sphingomyelin (SM; SM:ceramide ratio): +5–10%
Dosing and Drug Interactions
Endothelial/vascular support: 5–10g daily. FTY720/fingolimod (MS therapy; S1PR functional antagonist): Spirulina SPHK1/S1P elevation does not counter fingolimod (which acts by S1PR internalisation, not S1P competition); no pharmacological conflict. Ceramide-targeted cancer therapy (ceramide-producing agents: daunorubicin/etoposide): Spirulina ceramide reduction via aSMase/SPT suppression may counter ceramide-mediated cancer apoptosis; theoretical caution in active cancer chemotherapy. Anti-TNF biologics (infliximab/etanercept): Spirulina NF-κB/TNF-α suppression: complementary to anti-TNF; additive aSMase/ceramide reduction. SPHK1 inhibitors (SKI-II; experimental cancer): Spirulina SPHK1 activation is mechanistically opposite to experimental SPHK1 inhibitor cancer therapy; separate concerns. Summary: S1P +10–20%, ceramide −20–30%, TEER +10–20%; dosing 5–10g daily. NK concern: low (ceramide-chemotherapy theoretical caution).